GNA Biosolutions, based at the Science Hotspot Martinsried near Munich, develops diagnostic instruments and assays for the ultrafast detection of pathogens. Our unique, proprietary technology, Pulse Controlled Amplification (PCA), has received awards for its innovative potential in the past. PCA technology, a further development of the PCR method, enables highly sensitive molecular tests in a matter of minutes in a wide range of applications, such as the detection of multi-resistant bacteria in hospitals and in many other areas where fast and reliable DNA analysis is particularly important.
We develop instruments and tests for the ultrafast detection of real "bugs", such as Sars-CoV-2, multi-resistant hospital germs, tuberculosis and other pathogens. Based on our Pulse Controlled Amplification technology, we can detect pathogens in a fraction of the time. We are looking for you as software architect and development lead for our embedded systems to be part of a multi-disciplinary team to provide advanced diagnostic solutions.